Centene Corporation
CNC
$62.22
+2.27%
Centene Corporation is a managed care organization that focuses on government-sponsored healthcare plans, including Medicaid, Medicare, and individual health insurance exchanges, serving approximately 20 million medical members as of December 2025. As a leading player in the Medicaid managed care space, Centene differentiates itself through its scale and specialization in government programs, with Medicaid comprising about 64% of its membership. The current investor narrative centers on the company's strategic pivot toward profitability amid a significant loss of Affordable Care Act (ACA) membership, which has prompted cost-cutting measures such as voluntary staff buyouts. Additionally, recent positive developments, including a larger-than-expected Medicare Advantage payment increase from CMS, have boosted sector sentiment and raised hopes for improved revenue visibility and margin recovery.…
CNC
Centene Corporation
$62.22
Related headlines
Investment Opinion: Should I buy CNC Today?
Based on the analysis, I rate Centene as a 'Buy' with a thesis that its deeply discounted valuation, strong revenue growth, and favorable regulatory environment offer a compelling risk-reward, despite near-term profitability challenges. The consensus analyst rating of 'Buy' with an average target price of $70.67 supports this view, implying 13.6% upside from the current price.
Sign up to view all
CNC 12-Month Price Forecast
The AI assessment leans bullish, driven by the stock's deep valuation discount, strong revenue growth, and positive analyst sentiment. However, the medium confidence reflects the uncertainty surrounding membership stabilization and profitability. If the company can deliver consistent earnings and show progress in ACA membership, the stance would be upgraded to high confidence. Conversely, any negative surprises in membership or margins could shift the stance to neutral or bearish.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Centene Corporation's 12-month outlook, with a consensus price target around $70.67 and implied upside of +13.6% versus the current price.
Average Target
$70.67
0 analysts
Implied Upside
+13.6%
vs. current price
Analyst Count
—
covering this stock
Price Range
$56 - $85
Analyst target range
Centene is covered by 18 analysts, with a consensus recommendation of 'Buy' and a mean recommendation score of 2.43 (where 1 is Strong Buy and 5 is Sell). The average target price is $70.67, implying an upside of approximately 13.6% from the current price of $62.22. The distribution includes 10 Buy ratings, 6 Hold ratings, and 2 Sell ratings, indicating a moderately bullish sentiment. The target price range spans from a low of $56.00 to a high of $85.00, with the wide spread reflecting uncertainty about the company's ability to stabilize membership and improve margins. The high target of $85.00 assumes successful execution of cost-cutting measures and a rebound in ACA membership, while the low target of $56.00 prices in continued membership losses and margin pressure. Recent institutional actions have been largely neutral, with firms like Wells Fargo and RBC Capital maintaining their ratings, while B of A Securities and Truist Securities reiterate Buy ratings, suggesting a stable outlook among analysts.
Bulls vs Bears: CNC Investment Factors
Centene presents a compelling value opportunity with its deeply discounted valuation, strong revenue growth, and favorable regulatory tailwinds, but it is tempered by persistent profitability challenges and membership losses. The bull case is currently stronger, supported by the 138.67% stock rally and analyst consensus of 13.6% upside, yet the bear case highlights the fragility of earnings and high leverage. The most critical tension is whether the company can successfully execute its cost-cutting and margin recovery plan while stabilizing ACA membership; if it does, the stock could re-rate significantly higher, but failure could lead to a sharp correction. Overall, the evidence leans bullish, but investors should monitor quarterly earnings for signs of sustained profitability.
Bullish
- Massive 1-Year Rally Outperforms Market: CNC stock surged 138.67% over the past year, dramatically outpacing the S&P 500's 18.19% gain. This reflects strong investor confidence in the company's turnaround strategy and improving sector conditions, particularly the favorable CMS Medicare payment increase.
- Extremely Low Valuation Multiples: With a forward P/E of 12.05x and a price-to-sales ratio of 0.10x, CNC trades at a steep discount to the industry average PS of 0.50x. The PEG ratio of 0.01x suggests the market is pricing in minimal growth, offering significant upside if the company meets earnings expectations.
- Strong Revenue Growth Momentum: Q1 2026 revenue grew 7.13% YoY to $49.94 billion, with sequential acceleration from $40.81 billion in Q4 2024. The Medicaid segment, contributing $39.21 billion, provides a stable, government-backed revenue base that supports long-term growth.
- Positive Analyst Sentiment and Targets: Analysts maintain a consensus 'Buy' rating with an average target price of $70.67, implying 13.6% upside from the current $62.22. The high target of $85.00 suggests potential for 36.6% upside if the turnaround succeeds, reflecting confidence in management's cost-cutting and margin recovery plans.
Bearish
- Negative Earnings and Thin Margins: TTM EPS is -$0.33, with a net margin of -3.43% and operating margin of -3.91%. While Q1 2026 showed improvement (EPS of $3.13), the company's profitability remains fragile, and any operational misstep could reverse the recovery.
- ACA Membership Slump Pressures Revenue: Centene has experienced a significant loss of Affordable Care Act (ACA) membership, forcing cost-cutting measures like voluntary staff buyouts. This reduces revenue visibility and could lead to lower top-line growth if not offset by other segments.
- High Debt-to-Equity Ratio: Debt-to-equity stands at 0.94, indicating substantial leverage. With interest expenses of $164 million in Q1 2026, rising interest rates could strain cash flows and limit financial flexibility, especially if earnings remain volatile.
- Stock Near 52-Week High, Overbought Risks: Trading at $62.22, CNC is near its 52-week high of $69.36, with a 1-month decline of -8.97% suggesting potential overextension. The stock's beta of 1.077 indicates higher volatility than the market, and a pullback could be sharp if sentiment shifts.
CNC Technical Analysis
Centene's stock has exhibited a remarkable recovery over the past year, with a 1-year price change of +138.67%, significantly outperforming the S&P 500's +18.19% gain. The current price of $62.22 sits at approximately 89.7% of its 52-week range (between the low of $25.08 and high of $69.36), indicating the stock is trading near its highs, which typically reflects strong momentum but also potential overextension. The 6-month price change of +43.63% underscores a sustained uptrend, though the stock has pulled back from its July peak, suggesting a possible consolidation phase.
Beta
1.08
1.08x market volatility
Max Drawdown
-55.5%
Largest decline past year
52-Week Range
$25-$69
Price range past year
Annual Return
+138.7%
Cumulative gain past year
| Period | CNC Return | S&P 500 |
|---|---|---|
| 1m | -9.0% | +0.3% |
| 3m | +16.6% | +4.0% |
| 6m | +43.6% | +8.3% |
| 1y | +138.7% | +20.2% |
| ytd | +48.9% | +9.6% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CNC Fundamental Analysis
Centene's revenue trajectory shows steady growth, with the most recent quarter (Q1 2026) reporting revenue of $49.94 billion, a 7.13% year-over-year increase. This growth is driven primarily by the Medicaid segment, which contributed $39.21 billion, and the Commercial segment at $9.56 billion, though the company has experienced a membership slump in ACA plans, leading to cost-cutting initiatives. The multi-quarter trend reveals revenue growth accelerating from $40.81 billion in Q4 2024 to $49.94 billion in Q1 2026, indicating a robust top-line expansion despite operational challenges.
Quarterly Revenue
$49.9B
2026-03
Revenue YoY Growth
+7.1%
YoY Comparison
Gross Margin
21.9%
Latest Quarter
Free Cash Flow
$6.3B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CNC Overvalued?
Given that Centene's trailing twelve-month net income is negative (EPS of -$0.33), the price-to-sales (PS) ratio is the most appropriate valuation metric, currently at 0.10x, which is significantly lower than the industry average. The forward PE of 12.05x suggests the market expects a substantial earnings recovery, as analysts project EPS of $9.00 for the next fiscal year, implying a PEG ratio of 0.01x, which is extremely low and indicates potential undervaluation relative to growth. Compared to the sector, Centene trades at a steep discount, with a PS ratio of 0.10x versus the industry average of 0.50x, reflecting a 80% discount, which may be justified by its negative margins and operational risks but also presents a value opportunity if the turnaround succeeds.
PE
-3.0x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 3x~27x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-4.1x
Enterprise Value Multiple
Investment Risk Disclosure
Financial risks are significant, as Centene's trailing twelve-month net income is negative, with an EPS of -$0.33 and a net margin of -3.43%. The company's high debt-to-equity ratio of 0.94 and interest expenses of $164 million in Q1 2026 increase vulnerability to rising interest rates. While Q1 2026 showed a return to profitability with EPS of $3.13, the prior quarters' losses (Q2 2025: -$0.51, Q3 2025: -$13.50, Q4 2025: -$2.24) highlight earnings volatility. The negative operating margin of -3.91% indicates that core operations are not yet consistently profitable, and any further membership losses could exacerbate cash flow pressures.
FAQ
The key risks of holding CNC include: 1) Financial risk from negative earnings and high debt-to-equity ratio of 0.94, which could strain cash flows; 2) Competitive risk from larger managed care players and potential membership losses in the ACA segment; 3) Regulatory risk from changes in government healthcare policies, though the recent CMS payment increase is positive; 4) Market risk from the stock's high beta of 1.077, which amplifies market movements. The most severe risk is a failure to stabilize membership, which could lead to a decline to the 52-week low of $25.08.
The 12-month forecast for CNC is moderately bullish, with a base case probability of 50% targeting a range of $65-$75, aligning with the analyst average target of $70.67. The bull case (30% probability) targets $75-$85, driven by successful turnaround execution, while the bear case (20% probability) targets $50-$56, reflecting continued operational struggles. The most likely scenario is the base case, assuming gradual margin improvement and stable revenue growth.
CNC is currently undervalued relative to its peers and its own growth prospects. The forward P/E of 12.05x is low compared to the expected EPS of $9.00, and the PS ratio of 0.10x is an 80% discount to the industry average of 0.50x. The PEG ratio of 0.01x suggests the market is pricing in minimal growth, which is overly pessimistic given the company's revenue momentum. This valuation implies that the market expects continued operational challenges, but if the turnaround succeeds, the stock has significant upside potential.
CNC appears to be a good buy for investors with a higher risk tolerance, given its deep valuation discount (PS ratio of 0.10x vs. industry 0.50x) and strong revenue growth (7.13% YoY). The analyst consensus 'Buy' with a 13.6% upside to the average target price supports this view. However, the stock carries significant risks, including negative TTM earnings and ACA membership losses, which could lead to volatility. It is a good buy for those who believe in the turnaround story and can withstand potential drawdowns, but not for conservative investors seeking stability.
CNC is more suitable for long-term investment, given its turnaround nature and the time required for cost-cutting measures to translate into sustained profitability. The stock's high beta of 1.077 and recent volatility (1-month decline of -8.97%) make it risky for short-term trading. A minimum holding period of 12-18 months is recommended to allow the company to execute its strategic plan and for the market to recognize the value. Long-term investors could benefit from the deep valuation discount and favorable demographic trends in government-sponsored healthcare.